A new breakthrough in the field of anti-fibrosis! Ted Pharmaceuticals Class 1 new drug approved clinically

On October 26, China's State Drug Administration's Drug Review Center (CDE) announced that Ted Pharmaceuticals 1 new drug TDI01 tablets have been approved for clinical trials to be developed for the treatment of idioid pulmonary fibrosis (IPF).
According to an earlier press release from Ted Pharmaceuticals, TDI01 is a new target ROCK2 highly selective inhibitor that treats all aspects of fibrosis development, clinically developing adaptations including non-alcoholic fatty hepatitis (NASH) and pulmonary fibrosis.
noted that TDI01 has been approved for clinical trials in the United States and is currently conducting Phase 1 clinical trials.
screenshot source: CDE official website According to public information, TDI01 is a new target, highly selective Rhho/Rho-related curling helical protein kinase 2 (ROCK2) inhibitor.
fibrosis is a fibrous connective tissue or generalized tissue formed by damage or long-term inflammation, which occurs in the liver, lungs and kidneys.
body response to injury involves the recombination of the kinetic protein cytoskeletes of multiple cells, while the assembly of the myocardial filament and the contraction of the myoglobulin are regulated by the ROCK family proteins (including ROCK1 and ROCK2).
show that TDI01 can inhibit ROCK2, but also inhibit the fibrosis process, anti-inflammatory and immunomodulation effect, the development of fibrosis in all aspects of the therapeutic role.
this time for TDI01 tablets approved clinically in China, to be developed for the treatment of idiotic pulmonary fibrosis.
iditable pulmonary fibrosis is a kind of indesopathic lung disease, according to statistics, there are about 3 million patients worldwide.
progressive scarring in the lungs of patients with IPAF, resulting in a sustained and irreversible decline in lung function and breathing difficulties, endangering the patient's life.
some patients may be treated with a lung transplant, but many are too weak to receive a lung transplant.
other existing treatments can only alleviate the symptoms of the disease and do not change its progression.
in addition to idydynetic pulmonary fibrosis, TDI01 tablets are expected to offer hope to other fibrosis patients such as NASH.
some fibrosis patients, the loss of control of the tissue will gradually lead to organ structure damage and functional decline, and even failure.
, there is an urgent clinical need for innovative therapies that improve fibrosis.
Ted Pharmaceuticals Class 1 new drug TDI01 tablets approved clinically, I hope that the clinical research of this product is progressing smoothly and bring innovative therapies to patients with fibrosis at an early time.